Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Hernando

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Frontiers in Nutrition|June 11, 2026
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) studyMaria Argente-Pla, Miguel Antonio Sampedro-Nuñez, Rocio Garcia-Carbonero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Efficacy of [<sup>177</sup>Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU studyMercedes Mitjavila, Paula Jimenez-Fonseca, Pilar Belló, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Nature Communications|April 4, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trialJaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, et al.
European Journal of Endocrinology|August 14, 2025
External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapyPaula Jimenez-Fonseca, Cristina Álvarez-Escola, Inmaculada Ballester Navarro, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2025
Does adjuvant mitotane impact cure rates in adrenocortical carcinoma? Insights from the ICARO-GETTHI/SEEN registryAlberto Carmona-Bayonas, Cristina Álvarez Escola, Inmaculada Ballester Navarro, et al.
The Oncologist|February 25, 2025
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) studyMaribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, et al.
Neuroendocrinology|January 28, 2021
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU StudyPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, et al.
The Oncologist|May 25, 2026
Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohortPau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Frontiers in Nutrition|June 11, 2026
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) studyMaria Argente-Pla, Miguel Antonio Sampedro-Nuñez, Rocio Garcia-Carbonero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Efficacy of [<sup>177</sup>Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU studyMercedes Mitjavila, Paula Jimenez-Fonseca, Pilar Belló, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Nature Communications|April 4, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trialJaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, et al.
European Journal of Endocrinology|August 14, 2025
External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapyPaula Jimenez-Fonseca, Cristina Álvarez-Escola, Inmaculada Ballester Navarro, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2025
Does adjuvant mitotane impact cure rates in adrenocortical carcinoma? Insights from the ICARO-GETTHI/SEEN registryAlberto Carmona-Bayonas, Cristina Álvarez Escola, Inmaculada Ballester Navarro, et al.
The Oncologist|February 25, 2025
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) studyMaribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, et al.
Neuroendocrinology|January 28, 2021
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU StudyPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, et al.
The Oncologist|May 25, 2026
Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohortPau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, et al.
Pageof 10